AXGN — AxoGen, Inc. stock price, charts and financials

QT81AxoGen, Inc.

AxoGen, Inc. (NASDAQ: AXGN) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
47.32
+0.89+1.92%
AXGNQT81AxoGen, Inc.·NASDAQ
47.32+1.92%
TA
Loading chart...
Screen all →
Snapshot
Index-P/E-EPS (ttm)-0.68Insider Own7.25%Shs Outstand53.76MPerf Week10.00%
Market Cap2.50BForward P/E68.14EPS next Y0.68Insider Trans-1.11%Shs Float52.20MPerf Month6.44%
Enterprise Value2.42BPEG0.33EPS next Q0.15Inst Own-Short Float10.43%Perf Quarter6.96%
Income-33.70MP/S9.94EPS this Y164.71%Inst Trans-Short Ratio4.30Perf Half Y36.96%
Sales251.17MP/B9.66EPS next Y54.87%ROA-11.00%Short Interest5.44MPerf YTD41.86%
Book/sh-P/C-EPS next 5Y30.60%ROE-17.88%52W High47.85 -1.11%Perf Year237.67%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-4.65%52W Low13.76 243.93%Perf 3Y452.74%
Dividend Est.-EV/EBITDA-Sales past 3/5Y17.41% 14.97%Gross Margin74.56%Volatility4.67% 5.61%Perf 5Y127.93%
Dividend TTM-EV/Sales9.64EPS Y/Y TTM-195.65%Oper. Margin-5.12%ATR (14)2.44Perf 10Y590.92%
Dividend Ex-DateJan 27, 2010Quick Ratio5.04Sales Y/Y TTM34.22%Profit Margin-13.36%RSI (14)64.89Recom2.16
Dividend Gr. 3/5Y- 75.54%Current Ratio6.60EPS Q/Q0.00%SMA2011.90%Beta1.14Target Price50.17
Payout0.00%Debt/Eq0.08Sales Q/Q22.81%SMA509.44%Rel Volume0.58Prev Close46.43
Employees622LT Debt/Eq0.50EarningsNov 04SMA20033.44%Avg Volume1.23MPrice47.32
IPO DateDec 17, 1986Option/ShortYes / YesEPS/Sales Surpr.-1.18% 3.92%Net Debt/EBITDA5.04Volume712,992Change1.92%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-30-26ReiteratedTruist Financial$55
Jul-30-26ReiteratedHC Wainwright & Co.Buy$50$53
Jul-29-26ReiteratedJefferiesBuy$50$55
Apr-29-26ReiteratedRaymond JamesOutperform$41$48
Apr-29-26ReiteratedHC Wainwright & Co.Buy$39$50
Apr-29-26ReiteratedCanaccord GenuityBuy$45$50
Apr-24-26ReiteratedCanaccord GenuityBuy$40$45
Feb-23-26ReiteratedRaymond JamesOutperform$36$41
Feb-19-26InitiatedWells FargoOverweight$40
Dec-05-25ReiteratedCanaccord GenuityBuy$27$37
Latest News
Aug-03-26
Jul-30-26
Jul-29-26
Jul-15-26
Jul-14-26
Jun-20-26
Company

AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue251225187
Cost of Goods Sold Incl. D&A635845
Gross Profit187167142
Selling, General and Administrative Excl. Other165142117
Research and Development373328
Other Operating Expense
-200
Operating Income-13-8-3
Interest Expense1388
Unusual Expense
Non-Operating Income (Expense)-802
Net Income Before Taxes-34-16-10
Income Taxes
000
Consolidated Net Income-34-16-10
Net Income From Continuing Operations-34-16-10
Net Income-34-16-10
EPS (Recurring)-0.67-0.34-0.23
EPS (Basic, Before Extraordinaries)-0.67-0.34-0.23
EPS (Diluted)-0.68-0.34-0.23
EBITDA-1406
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio
Price To Sales Ratio9.996.693.88
Gross Margin74.5074.2275.94
Operating Margin-5.18-3.56-1.60
Net Margin-13.55-7.11-5.35
Shares Outstanding534644
Market Capitalization2,5081,506725
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$52.00$39.93$27.86$15.79$3.72 Close Price0.00M2.64M5.29M7.93M10.58MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Weiler Kathy JohnsonDirectorJun 19 '26Option Exercise0.0028,300014,150Jun 23
Levine Alan MDirectorJun 19 '26Option Exercise0.0028,300050,893Jun 23
Burke William P. Mr.DirectorJun 19 '26Option Exercise0.0028,300014,250Jun 23
Wendell Amy McBrideDirectorJun 19 '26Option Exercise0.0028,3000107,976Jun 23
THOMAS PAULDirectorJun 19 '26Option Exercise0.0037,734032,395Jun 23
TYNDALL JOSEPH A.DirectorJun 19 '26Option Exercise0.0028,300014,150Jun 23
JOHNSON JOHNDirectorJun 19 '26Option Exercise0.0028,300014,150Jun 23
Wendell Amy McBrideDirectorMay 08 '26Option Exercise14.851,64724,45895,473May 12
Wendell Amy McBrideDirectorMay 08 '26Sale42.601,64770,16293,826May 12
Hartley Lindsey MarieCFOMay 07 '26Sale43.671,05145,89762,756May 08
JOHNSON JOHNDirectorMay 07 '26Option Exercise7.0411,05077,79211,050May 08
JOHNSON JOHNDirectorMay 07 '26Sale43.2611,050477,9680May 08
Weiler Kathy JohnsonDirectorMay 07 '26Option Exercise6.9516,344113,59116,344May 08
Weiler Kathy JohnsonDirectorMay 07 '26Sale44.0916,344720,6230May 08
Kemp JensChief Marketing OfficerMay 07 '26Sale43.444,000173,76172,451May 08
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.